Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Genentech/Roche's Avastin (bevacizumab) will be the primary driver of the market to treat ovarian cancer if data from the agent's recent Phase III clinical trial proves favorable. This finding is despite the discontinuation of a Phase II study of bevacizumab for platinum- refractory ovarian cancer.

The new Pharmacor report entitled Ovarian Cancer finds that, pending regulatory approval, Avastin will be used as a first-line treatment in combination with chemotherapy to boost standard efficacy for patients with advanced stages of the disease.

"The increase in volume of drug per patient will likely arise from the introduction of novel immunotherapeutic and antiangiogenic agents administered concurrently with or following treatment with the current gold-standard therapy of carboplatin (Bristol-Myers Squibb's Paraplatin, generics) combined with paclitaxel (Bristol-Myers Squibb's Taxol, generics)," said Jude Nelson, analyst at Decision Resources, Inc. "Although the drug will not be used to treat platinum-refractory ovarian cancer, clinicians are highly optimistic about the future of the antiangiogenic Avastin and its potential efficacy as a combination therapy in first-line treatment of the disease."

About Ovarian Cancer

Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the Western world and the fifth-most-frequent cause of cancer death in women. Ovarian cancer, often referred to as the "silent killer," has a high mortality rate that is usually ascribed to late diagnosis because the disease often lacks early warning symptoms.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Despite a Slip in HMO Enrollments, Florida Remains an Attractive Healthcare Market, According the HealthLeaders-InterStudy

View Now